Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
29.73
+0.29 (0.99%)
At close: Mar 9, 2026, 4:00 PM EDT
29.73
0.00 (0.00%)
After-hours: Mar 9, 2026, 4:02 PM EDT
Enliven Therapeutics Employees
Enliven Therapeutics had 62 employees as of December 31, 2024. The number of employees increased by 16 or 34.78% compared to the previous year.
Employees
62
Change (1Y)
16
Growth (1Y)
34.78%
Revenue / Employee
n/a
Profits / Employee
-$1,595,292
Market Cap
1.78B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62 | 16 | 34.78% |
| Dec 31, 2023 | 46 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Recursion Pharmaceuticals | 600 |
| Vericel | 357 |
| Zymeworks | 264 |
| Relay Therapeutics | 192 |
| Olema Pharmaceuticals | 122 |
| Definium Therapeutics | 106 |
| Trevi Therapeutics | 34 |
ELVN News
- 11 days ago - Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - PRNewsWire
- 2 months ago - Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars - Benzinga
- 2 months ago - Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones - PRNewsWire
- 2 months ago - Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development - PRNewsWire
- 3 months ago - Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - PRNewsWire
- 3 months ago - Enliven Therapeutics Announces New CEO to Drive Next Phase of Development - PRNewsWire
- 3 months ago - Enliven Therapeutics: Notable Early Signals, But Too Many Assumptions To Justify A Buy - Seeking Alpha
- 4 months ago - Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PRNewsWire